Beta Lactam Drugs Market - By Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, Combination), By Disease (Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Hospital Acquired Pneumonia, Ventilator Associated Pneumonia, Other Nosocomial Pneumonia, Blood Stream Infection, Other Diseases), By Route Of Administration (Oral, Intravenous, Others) And By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 193
Status: Published
Report Code: ARI100831
Beta-lactam and beta-lactamase inhibitors are majorly used for battling bacterial infections. They also kill or prevent the growth of harmful microorganisms. On the basis of the molecular structure, beta-lactam and beta-lactamase inhibitors drugs are catalogued into penicillin, carbapenem, cephalosporin, monobactam etc. The market for beta lactam has increased over the years owing to increased consumption in developing nations and rise in the commonness of infectious diseases. The restraining factor for the market could be the expiry of patent for prime branded formulations such as Cayston (2017), Doribax (June 2020), and Teflaro (2020).
The market for beta lactams has been segmented on various criteria such as by drug class, by disease, be route of administration and region. The market for the global beta lactam drug is dominated by Asia-pacific region which is mainly due to presence of low- and middle-income people in that region. Some of the major players in this market are Abbott Laboratories, Allergan Plc, GlaxoSmithKline plc, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd.
Analyst Commentary
The global market size of beta-lactam and beta-lactamase inhibitors in 2020 was 28.53 billion and is expected to reach 33.46 billion by 2027 at a CAGR of 2.3%.This is due to the prevalence of continuous R & D in the field of lactam drugs, this could be attributed to the increased number of diseases that are prevalent in the world, which is causing a lot of suffering the to the people. As per the report by WHO, The Deaths of children below five years of age each year is estimated for over 1.1 million from pneumonia, which is more than the number of deaths occurring from tuberculosis, AIDS, and malaria (in the same age group) combined. Therefore, it becomes necessary to intake antibiotics to inhibit its growth.
According to the report, Asia- pacific region holds the key to the market and dominated the market by holding more than 40% of the market share followed by North America which holds ¼ of the market. This is mainly due to presence of Old-Aged citizens among the developed countries of the west and selling of antibiotics without any prescription at the drug stores and pharmacies.
Based on the Drug class segment, the respiratory infection segment dominated the market with share of 1/5 of the total market in bet-lactam inhibitors in 2018. and is anticipated remain the same throughout the forecast period. This is due to increase in existence of lung diseases and hike in R&D on the drugs for curing the respiratory infections.
Recently, the demand for beta-lactam and beta-lactamase inhibitors is increasing, which is due to grown consumption in low- and middle-income countries (LMICs) and hike in generality of contagious diseases. In addition to this, growth of novel procedures for new beta-lactamase and beta-lactam inhibitors for tending bacteria related infections and a great number of clinical tests further drive the market growth. However, development of antibiotic resistance, operated by undue use of beta-lactamase and beta-lactam inhibitors and the amount of time taken for the regulatory approval is forecasted to hamper the growth of market. In Contrast, invention of advanced novel combination and prospect molecules prospect molecules and to treat antibiotic-resistant microbial infections are anticipated to offer noteworthy fruitful opportunities for the market players.
Segmentation
Beta lactam drug makes up 65% of the total antibiotics market. Thus, this market is very vast and can be segmented on the basis of Drug Class, Disease, Route of Administration and Region. On the basis of Segmentation by Drug Class the market is further segmented on the basis of Penicillin, Cephalosporin, Carbapenem, Monobactam and Combination, out of which Cephalosporin market has the largest market share among the others, as it holds the key to the Antibiotics Market., whereas the Combination would be the largest growing segment for the forecast period. On the Basis of Segmentation by Disease, the market can be further segmented to Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Nosocomial Pneumonia, Blood Stream Infection, Other Diseases, in which Respiratory infection holds the dominance in the segment. On the basis of Route of Administration, the market can further segment to Oral, Intravenous and Others.
Regional Analysis
On the basis of Region, the market can be segmented to North America, Europe, Asia-Pacific and Latin America Region. Asia-Pacific region is the dominating region worldwide for the global Beta lactam drug market and holds 2/5 of the market share. The main reason for this hike is the accessibility of infection-resistant antibiotics without any prescription, leading to the increased consumption of the antibiotics. As per the studies, the region following the Asia-Pacific is North America which accounts for more than 25% of the total market share of beta-lactamase and beta-lactam inhibitors in 2018 and it is anticipated to remain the same throughout the forecast period. The prevalence of disease is mainly in the country which is low to middle income. The lack of laws or restrictions by the government of the countries has also been a key driver and has acted as a stimulus for the Global beta lactam drugs market. The developed counties having ageing people is also likely to increase the market growth due to their low immunity and they being more prone to the infectious diseases.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Beta Lactam Drugs Market
Chapter 5. Global Beta Lactam Drugs Market Overview, By Drug Class, 2015 – 2027 (USD Billion)
5.1. Global Beta Lactam Drugs Market Share, By Drug Class, 2020 & 2027 (%)
5.1.1. Penicillin
5.1.1.1. Market Size and Projections,2015 – 2027 (USD Billion)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
5.1.2. Cephalosporin
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
5.1.3. Carbapenem
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
5.1.4. Monobactam
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
5.1.5. Combination
5.1.5.1. Market Size and Projections, 2015 - 2027 (USD Billion)
5.1.5.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
Chapter 6. Global Beta Lactam Drugs Market Overview, By Disease, 2015 – 2027 (USD Billion)
6.1. Global Beta Lactam Drugs Market Share, By Disease, 2020 & 2027 (%)
6.1.1. Urinary Tract Infection (excluding cUTI)
6.1.1.1. Market Size and Projections,2015 – 2027 (USD Billion)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.2. Respiratory Infection
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.3. Skin Infection
6.1.3.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.4. Complicated Urinary Tract Infection (cUTI)
6.1.4.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.4.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.5. Complicated Intra-Abdominal Infections (cIAI)
6.1.5.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.5.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.6. Nosocomial Pneumonia
6.1.6.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.6.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.7. Hospital Acquired Pneumonia
6.1.7.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.7.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.8. Ventilator Associated Pneumonia
6.1.8.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.8.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.9. Other Nosocomial Pneumonia
6.1.9.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.9.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.10. Blood Stream Infection
6.1.10.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.10.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
6.1.11. Other Diseases
6.1.11.1. Market Size and Projections, 2015 - 2027 (USD Billion)
6.1.11.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
Chapter 7. Global Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 – 2027 (USD Billion)
7.1. Global Beta Lactam Drugs Market Share, By Route of Administration, 2020 & 2027 (%)
7.1.1. Oral
7.1.1.1. Market Size and Projections,2015 – 2027 (USD Billion)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
7.1.2. Intravenous
7.1.2.1. Market Size and Projections, 2015 - 2027 (USD Billion)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
7.1.3. Others
7.1.3.1. Market Size and Projections, 2015 - 2027 (USD Billion)
7.1.3.2. Market Size and Projections, by Region, 2015 - 2027(USD Billion)
Chapter 8. Global Beta Lactam Drugs Market Overview, By Geography, 2015 - 2027 (USD Billion)
8.1. Global Beta Lactam Drugs Market Share, By Geography, 2015 - 2027(USD Billion)
8.1.1. Market Size and projections, by Countries, 2015 - 2027 (USD Billion)
8.1.2. Market Share and CAGR Comparison, by Countries, 2020 (%)
Chapter 9. North America Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
9.1. North America Beta Lactam Drugs Market Overview, 2020 & 2027 (%)
9.1.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.2. North America Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
9.1.3. North America Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
9.1.4. North America Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
9.1.5. North America Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027 (USD Billion)
9.1.5.1. U.S. Beta Lactam Drugs Market Overview, 2015 - 2027 (USD Billion)
9.1.5.1.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.5.1.2. U.S. Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027 (USD Billion)
9.1.5.1.3. U.S. Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027 (USD Billion)
9.1.5.1.4. U.S. Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027 (USD Billion)
9.1.5.2. Canada Beta Lactam Drugs Market Overview, 2015 - 2027 (USD Billion)
9.1.5.2.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.5.2.2. Canada Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027 (USD Billion)
9.1.5.2.3. Canada Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027 (USD Billion)
9.1.5.2.4. Canada Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027 (USD Billion)
9.1.5.3. Mexico Beta Lactam Drugs Market Overview, 2015 - 2027 (USD Billion)
9.1.5.3.1. Market size and projections, 2015 - 2027 (USD Billion)
9.1.5.3.2. Mexico Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027 (USD Billion)
9.1.5.3.3. Mexico Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027 (USD Billion)
9.1.5.3.4. Mexico Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027 (USD Billion)
Chapter 10. Europe Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
10.1. Europe Beta Lactam Drugs Market Overview, 2020 & 2027 (%)
10.1.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.2. Europe Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027 (USD Billion)
10.1.3. Europe Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027 (USD Billion)
10.1.4. Europe Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027 (USD Billion)
10.1.5. Europe Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1.5.1. Germany
10.1.5.1.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.1.2. Germany Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027 (USD Billion)
10.1.5.1.3. Germany Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027 (USD Billion)
10.1.5.1.4. Germany Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027 (USD Billion)
10.1.5.1.5. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.1.6. France Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
10.1.5.1.7. France Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
10.1.5.1.8. France Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
10.1.5.2. UK
10.1.5.2.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.2.2. UK Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
10.1.5.2.3. UK Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
10.1.5.2.4. UK Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
10.1.5.3. Italy
10.1.5.3.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.3.2. Italy Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
10.1.5.3.3. Italy Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
10.1.5.3.4. Italy Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
10.1.5.4. Spain
10.1.5.4.1. Market size and projections, 2015 - 2027 (USD Billion)
10.1.5.4.2. Spain Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
10.1.5.4.3. Spain Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
10.1.5.4.4. Spain Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
10.1.5.5. Rest of Europe
10.1.5.5.1. Market size and projections, 2015 – 2025
10.1.5.5.2. Rest of Europe Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
10.1.5.5.3. Rest of Europe Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
10.1.5.5.4. Rest of Europe Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
Chapter 11. Asia Pacific Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
11.1. Asia Pacific Beta Lactam Drugs Market Overview, 2020 & 2027(%)
11.1.1. Market size and projections, 2015 - 2027(USD Billion)
11.1.2. Asia Pacific Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
11.1.3. Asia Pacific Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
11.1.4. Asia Pacific Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
11.1.5. Asia Pacific Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
11.1.5.1. India
11.1.5.1.1. Market size and projections, 2015 - 2027(USD Billion)
11.1.5.1.2. India Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
11.1.5.1.3. India Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
11.1.5.1.4. India Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
11.1.5.2. China
11.1.5.2.1. Market size and projections, 2015 - 2027(USD Billion)
11.1.5.2.2. China Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
11.1.5.2.3. China Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
11.1.5.2.4. China Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
11.1.5.3. Japan
11.1.5.3.1. Market size and projections, 2015 - 2027(USD Billion)
11.1.5.3.2. Japan Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
11.1.5.3.3. Japan Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
11.1.5.3.4. Japan Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
11.1.5.4. South Korea
11.1.5.4.1. Market size and projections, 2015 - 2027(USD Billion)
11.1.5.4.2. South Korea Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
11.1.5.4.3. South Korea Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
11.1.5.4.4. South Korea Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market size and projections, 2015 - 2027(USD Billion)
11.1.5.5.2. Rest of Asia Pacific Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
11.1.5.5.3. Rest of Asia Pacific Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
11.1.5.5.4. Rest of Asia Pacific Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
Chapter 12. Middle East & Africa Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
12.1. Middle East & Africa Beta Lactam Drugs Market Overview, 2015 - 2027(USD Billion)
12.1.1. Market size and projections, 2015 - 2027(USD Billion)
12.1.2. Middle East & Africa Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
12.1.3. Middle East & Africa Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
12.1.4. Middle East & Africa Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
12.1.5. Middle East & Africa Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
12.1.5.1. GCC
12.1.5.1.1. Market size and projections, 2015 - 2027(USD Billion)
12.1.5.1.2. GCC Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
12.1.5.1.3. GCC Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
12.1.5.1.4. GCC Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
12.1.5.1.5. Market size and projections, 2015 - 2027(USD Billion)
12.1.5.1.6. South Africa Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
12.1.5.1.7. South Africa Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
12.1.5.1.8. South Africa Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
12.1.5.2. Rest of Middle East & Africa
12.1.5.2.1. Market size and projections, 2015 - 2027(USD Billion)
12.1.5.2.2. Rest of Middle East & Africa Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
12.1.5.2.3. Rest of Middle East & Africa Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
12.1.5.2.4. Rest of Middle East & Africa Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
Chapter 13. South America Beta Lactam Drugs Market Overview, By Countries, 2015 - 2027(USD Billion)
13.1. South America Beta Lactam Drugs Market Overview, 2015 - 2027(USD Billion)
13.1.1. Market size and projections, 2015 - 2027(USD Billion)
13.1.2. South America Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
13.1.3. South America Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
13.1.4. South America Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
13.1.5. South America Beta Lactam Drugs Market Overview, By Countries, 2015- 2026(USD Billion)
13.1.6. Brazil
13.1.6.1. Market size and projections, 2015 - 2027(USD Billion)
13.1.6.2. Brazil Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
13.1.6.3. Brazil Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
13.1.6.4. Brazil Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
13.1.7. Argentina
13.1.7.1. Market size and projections, 2015 - 2027(USD Billion)
13.1.7.2. Argentina Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
13.1.7.3. Argentina Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
13.1.7.4. Argentina Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
13.1.8. Rest of South America
13.1.8.1. Market size and projections, 2015 – 2027
13.1.8.2. Rest of South America Beta Lactam Drugs Market Overview, By Drug Class, 2015 - 2027(USD Billion)
13.1.8.3. Rest of South America Beta Lactam Drugs Market Overview, By Disease, 2015 - 2027(USD Billion)
13.1.8.4. Rest of South America Beta Lactam Drugs Market Overview, By Route Of Administration, 2015 - 2027(USD Billion)
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2020
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New product development
Chapter 15. Key Vendor Analysis
15.1. Abbott Laboratories
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Product Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Allergan Plc
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Product Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. GlaxoSmithKline plc
15.4. Merck & Co. Inc
15.5. Novartis International AG
15.6. Others
Chapter 16. Beta Lactam Drugs Market Cost Analysis
16.1. Key Raw Materials Analysis
16.1.1. Key Raw Materials
16.1.2. Price Trend of Beta Lactam Drugs Market Key Raw Materials
16.1.3. Key Suppliers of Raw Materials
16.1.4. Market Concentration Rate of Raw Materials
Chapter 17. Industrial Chain, Sourcing Strategy and Downstream Buyers
17.1. Industrial Chain Analysis
17.2. Upstream Raw Materials Sourcing
17.3. Raw Materials Sources of Beta Lactam Drugs Market Major Manufacturers in 2020
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Client
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Technology Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Technology Progress in Related Industry
19.2. Consumer Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Beta Lactam Drugs Market share, By Drug Class, 2020 & 2027 (%)
10. Global Beta Lactam Drugs Market, by Penicillin, By Drug Class, 2015 - 2027(USD Billion)
11. Global Beta Lactam Drugs Market, by Cephalosporin, By Drug Class, 2015 - 2027(USD Billion)
12. Global Beta Lactam Drugs Market, by Carbapenem, By Drug Class, 2015 - 2027(USD Billion)
13. Global Beta Lactam Drugs Market, by Monobactam, By Drug Class, 2015 - 2027(USD Billion)
14. Global Beta Lactam Drugs Market, by Combination, By Drug Class, 2015 - 2027(USD Billion)
15. Global Beta Lactam Drugs Market share, By Disease, 2020 & 2027 (%)
16. Global Beta Lactam Drugs Market, by Urinary Tract Infection (excluding cUTI), By Disease, 2015 - 2027(USD Billion)
17. Global Beta Lactam Drugs Market, by Respiratory Infection, By Disease, 2015 - 2027(USD Billion)
18. Global Beta Lactam Drugs Market, by Skin Infection, By Disease, 2015 - 2027(USD Billion)
19. Global Beta Lactam Drugs Market, by Complicated Urinary Tract Infection (cUTI), By Disease, 2015 - 2027(USD Billion)
20. Global Beta Lactam Drugs Market, by Complicated Intra-Abdominal Infections (cIAI), By Disease, 2015 - 2027(USD Billion)
21. Global Beta Lactam Drugs Market, by Nosocomial Pneumonia, By Disease, 2015 - 2027(USD Billion)
22. Global Beta Lactam Drugs Market, by Hospital Acquired Pneumonia, By Disease, 2015 - 2027(USD Billion)
23. Global Beta Lactam Drugs Market, by Ventilator Associated Pneumonia, By Disease, 2015 - 2027(USD Billion)
24. Global Beta Lactam Drugs Market, by Other Nosocomial Pneumonia, By Disease, 2015 - 2027(USD Billion)
25. Global Beta Lactam Drugs Market, by Other Blood Stream Infection, By Disease, 2015 - 2027(USD Billion)
26. Global Beta Lactam Drugs Market, by Other Other Diseases, By Disease, 2015 - 2027(USD Billion)
27. Global Beta Lactam Drugs Market share, By Route of Administration, 2020 & 2027 (%)
28. Global Beta Lactam Drugs Market, by Oral, By Route Of Administration 2015 - 2027(USD Billion)
29. Global Beta Lactam Drugs Market, by Intravenous, By Route Of Administration 2015 - 2027(USD Billion)
30. Global Beta Lactam Drugs Market, by Others, By Route Of Administration 2015 - 2027(USD Billion)
31. Global Beta Lactam Drugs Market share, by region, 2020 & 2027 (%)
32. North America Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
33. North America Beta Lactam Drugs Market share, by Countries, 2020 & 2027 (%)
34. U.S. Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
35. Canada Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
36. Europe Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
37. Europe Beta Lactam Drugs Market share, by Countries, 2020 & 2027 (%)
38. Spain Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
39. UK Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
40. Italy Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
41. Germany Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
42. France Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
43. Rest of Europe Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
44. Asia-Pacific Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
45. Asia-Pacific Beta Lactam Drugs Market share, by Countries, 2020 & 2027 (%)
46. China Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
47. India Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
48. Australia Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
49. Japan Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
50. Rest of Asia-Pacific Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
51. Middle East & Africa Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
52. Middle East & Africa Beta Lactam Drugs Market share, by Countries, 2020 & 2027 (%)
53. GCC Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
54. South Africa Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
55. Rest Of Middle East & Africa Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
56. South America Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
57. Brazil Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
58. Mexico Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
59. Argentina Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
60. Rest of South America Beta Lactam Drugs Market, 2020 - 2027(USD Billion)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Beta Lactam Drugs Market, 2015-2027(USD Billion)
4. Global Beta Lactam Drugs Market requirement, by country, 2015-2027,(USD Billion)
5. North America Beta Lactam Drugs Market, By Drug Class, 2015-2027(USD Billion)
6. North America Beta Lactam Drugs Market, By Disease, 2015-2027(USD Billion)
7. North America Beta Lactam Drugs Market, By Route Of Administration, 2015-2027(USD Billion)
8. Europe Beta Lactam Drugs Market, By Drug Class, 2015-2027(USD Billion)
9. Europe Beta Lactam Drugs Market, By Disease, 2015-2027(USD Billion)
10. Europe Beta Lactam Drugs Market, By Route Of Administration, 2015-2027(USD Billion)
11. Asia Pacific Beta Lactam Drugs Market, By Drug Class, 2015-2027(USD Billion)
12. Asia Pacific Beta Lactam Drugs Market, By Disease, 2015-2027(USD Billion)
13. Asia Pacific Beta Lactam Drugs Market, By Route Of Administration, 2015-2027(USD Billion)
14. Middle East & Africa Beta Lactam Drugs Market, By Drug Class, 2015-2027(USD Billion)
15. Middle East & Africa Beta Lactam Drugs Market, By Disease, 2015-2027(USD Billion)
16. Middle East & Africa Beta Lactam Drugs Market, By Route Of Administration, 2015-2027(USD Billion)
17. South America Beta Lactam Drugs Market, By Drug Class, 2015-2027(USD Billion)
18. South America Beta Lactam Drugs Market, By Disease, 2015-2027(USD Billion)
19. South America Beta Lactam Drugs Market, By Route Of Administration, 2015-2027(USD Billion)
20. Global Beta Lactam Drugs Market, Company Market Share, 2020 (%)
21. Abbott Laboratories: Product Benchmarking
22. Abbott Laboratories: Financial Performance
23. Allergan Plc: Product Benchmarking
24. Allergan Plc: Financial Performance
25. GlaxoSmithKline plc: Product Benchmarking
26. GlaxoSmithKline plc: Financial Performance
27. Merck & Co. Inc: Product Benchmarking
28. Merck & Co. Inc: Financial Performance
29. Novartis International AG: Product Benchmarking
30. Novartis International AG: Financial Performance
The Leading Key Players in Beta Lactam Drugs Market
Abbott Laboratories
Allergan Plc
GlaxoSmithKline plc
Pfizer Inc.
Sanofi
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Teva Pharmaceutical Industries Ltd
